Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1074 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

BMS Q2 net sales up

Net earnings attributable to BMS were $902m, compared to $927m for the same period in the prior year. For the six months ended 30 June 2011 net sales

Health Canada approves Janssen prostate cancer drug

Zytiga is indicated with prednisone for the treatment of men with metastatic prostate cancer (castration-resistant prostate cancer) who have received prior chemotherapy containing docetaxel. The results from a

RegeneRx to start RGN-259 Phase 2 trial

The trial which will be conducted by ORA, an ophthalmic contract research organization, will start patient enrollment in next month. In the trial, the patients will be given

SkyePharma, Sanofi in pact for Flutiform

As per the terms of the contract, Sanofi is responsible to pay initial, approval and sales milestones to SkyePharma including single digit percentage on net sales. The tie

Michigan chooses SRS EHR technology

Michigan Eye Institute is an integrated eye-care practice with facilities in five locations in the Flint area of Michigan, US. Michigan Eye Institute MD Jeffrey Diskin said the

Lexicon concludes Phase 1 IBS-d drug trial

The trial results suggested that the drug was well tolerated at all dose levels and showed reduction in serotonin synthesis compared to placebo. The data from the study

Watson rolls out generic contraceptive pill

Seasonique is a combination of female hormones that helps in preventing ovulation. Seasonique makes changes in the cervical mucus and uterine lining, to make it harder for sperm

Humabs, MRC discover new flu therapeutic

FI6 is a neutralizing antibody which binds and neutralizes both Group 1 and Group 2 human and animal influenza A viruses. The researchers were able to culture single